Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Biosante Pharma Charts. Click Here for more Biosante Pharma Charts.](/p.php?pid=staticchart&s=A%5EBPA&p=8&t=15)
BioSante Pharmaceuticals (AMEX: BPA) today announced that BioSante
management will present a corporate overview and update at upcoming
conferences. The conferences are:
The Flaherty Financial News & Wall Street Research Small Cap
Conference on August 14, 2007 at 10:20 a.m. local time at the Penn
Club of New York.
The RedChip Small-Cap Investor Conference on August 16, 2007 at 11:00
a.m. and the Keynote address at 12:30 p.m. local time at the
Waldorf-Astoria Hotel New York.
The Noble Financial TWO DOUBLE-O-SEVEN conference on August 20, 2007
at 1:00 p.m. local time at the Orient Express Hotel in Charleston,
South Carolina.
A live audio webcast of BioSante’s
presentation at the RedChip and Noble conferences can be accessed on the
internet by visiting www.biosantepharma.com.
An archive of these presentations will be available at the same address.
These conferences each feature companies presenting to a diverse group
of investors, portfolio managers and analysts interested in the
biotechnology and pharmaceuticals sectors as well as industry
representatives.
About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat
both men and women. These hormone therapy products are gel formulations
for transdermal administration that deliver bio-identical estradiol and
testosterone. BioSante's lead products include Elestrin™
(estradiol gel) developed through FDA approval by BioSante indicated for
the treatment of moderate-to-severe vasomotor symptoms associated with
menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc.,
BioSante's licensee, and LibiGel®
(transdermal testosterone gel) in Phase III clinical development by
BioSante for the treatment of female sexual dysfunction (FSD). Also in
development is Bio-T-Gel™, a testosterone gel
for male hypogonadism, and an oral contraceptive in Phase II clinical
development using BioSante patented technology. The current market in
the U.S. for estrogen and testosterone products is approximately $2.5
billion and for oral contraceptives approximately $3.0 billion. The
company also is developing its calcium phosphate nanotechnology (CaP)
for novel vaccines, including hepatitis B, avian flu and biodefense
vaccines for toxins such as anthrax, as well as a system for delivering
drugs via alternative routes of administration and for aesthetic
medicine. Additional information is available online at www.biosantepharma.com.